Efficacy of sotagliflozin among older adults: a pooled analysis of SCORED and SOLOIST-WHF

30 August 2025 (08:51 - 09:09)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Rahul Aggarwal

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?

Professor D. Bhatt (New York City, US)

Presentation thumbnail

Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis

Professor S. Mulvagh (Halifax, CA)

Abstract Slides Video

Presentation thumbnail

Undertreatment of women with lipid-lowering therapies in four European countries: results from the prospective, non-interventional MILOS Study

Professor I. Gouni-Berthold (Cologne, DE)

Abstract Slides Video

Presentation thumbnail

Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT

Doctor D. Bhatt (New York City, US)

Abstract Slides Video

Access the full session

Session thumbnail

Closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?

The Event

Event poster

ESC Congress 2025

30 August 2025 08:51 CET

You may be interested in

Congress Presentation

Sotagliflozin is effective in reducing heart failure risk of events in patients with HFpEF

Congress Presentation

Clinical efficacy of sotagliflozin for heart failure outcomes across cardiac biomarker levels in SCORED

Congress Presentation

Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources